TABLE 3.
Susceptibility of HIV-1 and HIV-2 isolates to cabotegravir in spreading infections of CEMss cells
| Isolate by HIV type | Group/subtype | EC50 (nM)a | No. of assaysb |
|---|---|---|---|
| HIV-1 | |||
| 92UG029 | M/A | 0.21 ± 0.072 | 3 |
| NL4-3 | M/B | 0.15 ± 0.029 | 4 |
| HIV-2 | |||
| ROD9 | A | 0.14 ± 0.056 | 5 |
| ST | A | 0.25 ± 0.014 | 3 |
| CBL-20 | A | 1.0 ± 0.82 | 2 |
| CBL-23 | A | 0.16 ± 0.059 | 3 |
| CDC77618 | A | 0.85 ± 0.57 | 3 |
| CDC310319 | B | 0.99 ± 0.90 | 6 |
| EHO | B | 0.20 ± 0.027 | 2 |
| DIL | B | 1.3 ± 1.1 | 3 |
a
Values are means ± SD. These assays were performed using cabotegravir from GlaxoSmithKline, Inc.
b
Independent dose-response assays performed for each strain.